Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease

Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease

Lay Summary Despite a high approval rate, there were unnecessary delays in therapy due to prior authorizations. This study identified the impact of type of IBD, FDA-labeled indication, and dose escalations on approvals.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Inflammatory bowel diseases 2023-10, Vol.29 (10), p.1658-1661
Hauptverfasser: Choi, David K, Cohen, Nathaniel A, Choden, Tenzin, Cohen, Russell D, Rubin, David T
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Lay Summary Despite a high approval rate, there were unnecessary delays in therapy due to prior authorizations. This study identified the impact of type of IBD, FDA-labeled indication, and dose escalations on approvals.
ISSN:1078-0998
1536-4844
DOI:10.1093/ibd/izad012